Gilead, Medicines Patent Pool deal

Gilead expanded a 2011 deal with the Medicines Patent Pool to include non-exclusive rights for tenofovir alafenamide fumarate (TAF) for HIV and HBV infection. After the drug’s U.S. approval, MPP can sublicense the drug to Indian and Chinese generic drug companies, which can distribute it in 112 developing countries. The sublicenses are royalty bearing except in the case of pediatric formulations. In July 2011, Gilead granted MPP non-exclusive rights to HIV medicines elvitegravir, cobicistat and elvitegravir/cobicistat/emtricitabine/tenofovir. The pool was established in 2010 by UNITAID to allow companies to obtain a license to market generic versions of patented HIV/AIDS drugs in developing countries (see BioCentury, July 18, 2011). ...